Terms: = Lymphoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
1541 results:
1. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
Bilgin B; Kuralay Y; Yucel S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):215. PubMed ID: 38668879
[TBL] [Abstract] [Full Text] [Related]
2. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
[TBL] [Abstract] [Full Text] [Related]
3. New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on
Saw SPL; Le X; Hendriks LEL; Remon J
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e432516. PubMed ID: 38560815
[TBL] [Abstract] [Full Text] [Related]
4. Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy.
Wu F; Rittberg R; Lim K; Ho C
BMJ Case Rep; 2024 Mar; 17(3):. PubMed ID: 38531551
[TBL] [Abstract] [Full Text] [Related]
5. Outcome differences by sex in oncology clinical trials.
Kammula AV; Schäffer AA; Rajagopal PS; Kurzrock R; Ruppin E
Nat Commun; 2024 Mar; 15(1):2608. PubMed ID: 38521835
[TBL] [Abstract] [Full Text] [Related]
6. Genomic testing and targeted therapy of non-small cell lung cancer in China: a nationwide survey of physicians and clinical pathologists.
Wang J; Ying J; Wang Z; Meng X; Wu M; Qian C
Ann Palliat Med; 2024 Mar; 13(2):221-229. PubMed ID: 38509647
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
8. Survival benefit in egfr-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract] [Full Text] [Related]
9. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract] [Full Text] [Related]
10. The association of genomic alterations with PD-L1 expression in Chinese patients with egfr/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract] [Full Text] [Related]
11. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
12. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
13. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
14. Molecular analysis of endobronchial ultrasound needle aspirates in patients with non-small cell lung cancer: Results from the SCOPE database.
Vakil E; Dumoulin E; Stollery D; Gillson AM; MacEachern P; Dhaliwal I; Mitchell M; Li P; Schieman C; Romatowski N; Chee AC; Tyan CC; Fortin M; Hergott CA; Tremblay A
Cytopathology; 2024 May; 35(3):378-382. PubMed ID: 38349229
[TBL] [Abstract] [Full Text] [Related]
15. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis.
Zhao T; Yi J; Luo D; Liu J; Fan X; Wu Q; Wang W
World J Surg Oncol; 2024 Feb; 22(1):41. PubMed ID: 38303008
[TBL] [Abstract] [Full Text] [Related]
17. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.
Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820
[TBL] [Abstract] [Full Text] [Related]
18. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating egfr and activating the PI3K/Akt signaling.
Wang Z; Zhou T; Chen X; Zhu X; Liao B; Liu J; Li S; Tan T; Liu Y
Neoplasma; 2023 Dec; 70(6):761-776. PubMed ID: 38247332
[TBL] [Abstract] [Full Text] [Related]
19. The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer.
Lasala R; Romagnoli A; Santoleri F; Isgrò V; Confalonieri C; Costantini A; Enrico F; Russo G; Polidori P; Di Paolo A; Malorgio F; Beretta G; Musicco F
Eur J Clin Pharmacol; 2024 Apr; 80(4):519-527. PubMed ID: 38244052
[TBL] [Abstract] [Full Text] [Related]
20. Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.
Tomkins-Netzer O; Niederer R; Greenwood J; Fabian ID; Serlin Y; Friedman A; Lightman S
Prog Retin Eye Res; 2024 Mar; 99():101245. PubMed ID: 38242492
[TBL] [Abstract] [Full Text] [Related]
[Next]
